NEW YORK, Oct. 22, 2021 /PRNewswire/ -- Defiance ETFs
announced today that the Board of Trustees of ETF Series Solutions
(the "Trust") has determined to close and liquidate the Defiance
Nasdaq Junior Biotechnology ETF (NASDAQ: IBBJ) (the "Fund")
effective immediately after the close of business on December 3, 2021. Defiance ETFs recommended
the liquidation and closure of the Fund after consideration of the
Fund's prospects for growth, among other factors.
The Fund's last day of trading will be December 2, 2021, which will also be the final
day for creation unit orders by authorized participants. The Fund
will conclude operations and distribute the remaining proceeds to
shareholders promptly after December 3,
2021. Shareholders who do not sell their Fund shares by this
date will have their shares automatically redeemed for cash based
on the Fund's net asset value (NAV). Customary brokerage charges
may apply to transactions to sell Fund shares. Shareholders should
contact their tax advisor to discuss the income tax consequences of
the liquidation.
For additional information, please call 1-833-333-9383.
The Fund's investment objectives, risks, charges, and
expenses must be considered carefully before investing. The
prospectus and summary prospectus contain this and other important
information about the investment company. The prospectus can be
obtained by calling 1-833-333-9383 Please read it carefully before
investing.
Investing involves risk. Principal loss is possible.
A commission may apply when buying or selling an ETF.
Defiance ETFs are distributed by Foreside Fund Services,
LLC.
Contact:
Defiance ETFs
1-833-333-939
info@defianceetfs.com
View original
content:https://www.prnewswire.com/news-releases/defiance-announces-fund-closure-301406702.html
SOURCE Defiance ETFs